Symetis has developed a minimally invasive heart valve replacement solution, the Symetis Acurate TA™ system, based on proprietary geometry and delivery technology. The product received CE Mark in September 2011 and is well positioned to target the ca. USD 2 billion transcatheter aortic valve implantation (TAVI) market worldwide. The Acurate TA™ system offers unique self-positioning design, resulting in unmatched positioning tolerance and ease of use for the physician. The company is based in Lausanne, Switzerland.

Company Info
Country: Switzerland
Industry:    Biotech
Sector: medical technology
Status: Realized
Vehicle: Endeavour II LP

Company website

Endeavour Vision Team
Damien Tappy
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions